Unprecedented PK-PD correlations in-Vivo Pharmacology Learn how Christian Schnell, Associate Director Oncology NIBR, Novartis Pharma AG, Basel, CH reached his conclusions. Now available on demand. Registration for access < here >.

Have you ever wanted to get more out of your in-vivo pharmaceutical studies? Have a burning question about programmable pumps and implication of refinement and reduction of animal use? Join Christian Schnell in his upcoming webinar on Programmable pumps for compounds delivery in oncology research: implication for refinement and reduction of animal use. More information and registration < here >

iPRECIO Programmable Minipumps for continuous delivery lenalidomide (LLD) in chronic lymphocytic leukemia (CLL). Video, https://youtu.be/d8CHR7et5zs from Start to 7 minutes: Rodent Studies of PK, Safety and Tolerability of LLD in Healthy and SCID Mice by Dr Jamie Oliver Chief Medical Officer of Starton Therapeutics (https://startontx.com/). IMS/SMP-300 for mice or larger used. Photo of SMP-200 for rats of larger shown.

New review article on iPRECIO^® - Linkedin Article – “Programmable pumps offer precise and translatable delivery of compounds to stress-free animals”
https://www.linkedin.com/pulse/programmable-pumps-offer-precise-translatable-delivery-tsung-tan/?trackingId=i9CxNGMbQJye6JF6HVLJSw%3D%3D

US20200330445A1: Continuous delivery of lenalidomide and other immunomodulatory agents
"After the tumor reached an average size of 100-150 mm, iPrecio pump was surgically implanted into each of the mice . Dosing began twenty - four hours post pump implantation. Each of Groups 3-6 was treated lenalidomide via continuous subcutaneous infusion at different hourly rate. The dosing lasted 14 days followed by one day off the treatment and lasted for another 14 days . The iPrecio pump was replaced after 14 days." For full reference: - Click -